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Abstract 
 
Objective: The interplay between oxidative stress and inflammation is crucial in the 
pathogenesis of atherosclerosis. The adaptor protein p66Shc is implicated in atherogenesis 
and oxidative stress related responses in animal models of diseases. However, its role in 
humans remains to be defined. In this study, we hypothesized that expression of p66Shc 
increases in peripheral blood monocytes of patients affected by acute coronary syndromes 
(ACS). 
Methods: Male subjects aged 59 ± 4 (mean ± SD) years admitted for cardiac catheterization 
were subdivided in three groups: a) no local stenosis for the control group, b) at least one  
stenosis ≥ 75% in either left, circumflex or right coronary artery for the coronary artery 
disease (CAD) group or c) ST-elevation/non-ST-elevation myocardial infarction for the ACS 
group. Monocytes were isolated from whole blood and p66Shc RNA levels were determined 
by quantitative real time PCR. 
Results: p66Shc RNA levels were increased in ACS patients as compared to CAD (p = 0.007) 
and controls (p = 0.0249). Furthermore, malondialdehyde (MDA) and C-reactive protein 
(CRP) were increased in plasma of ACS patients. Levels of MDA correlated positively to 
p66Shc (r = 0.376, p = 0.01). Our data demonstrate increased p66Shc levels in monocytes of 
ACS but not CAD patients. 
Conclusion: This study suggests an involvement of p66Shc in the transition of a stable CAD 
to an ACS patient. p66Shc was associated with states of increased oxidative stress. Further 
work is needed to understand whether p66Shc may represent a possible pharmacological 
target or whether it represents an interesting novel biomarker.  
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Introduction 
 
Oxidative stress plays an important role in the pathogenesis of atherosclerosis, leading to 
cardiovascular complications such as myocardial infarction and stroke [1]. Classical 
cardiovascular risk factors (e.g. diabetes mellitus, dyslipidemia, smoking and age) increase 
systemic oxidative stress. As a consequence, nitric oxide availability decreases and 
endothelial dysfunction occurs as an early landmark of atherogenesis [2]. Oxidative stress 
triggers apoptosis, as seen in atherosclerotic plaques, and influences expression patterns of 
vascular cytokines and growth hormones, eventually resulting in a chronic inflammatory state 
typical of atherosclerosis [3]. Reactive oxygen species (ROS) are crucially involved in 
mediating the effects of inflammation by directly oxidizing target proteins and also by acting 
as second messengers in several redox responses [4]. Many insights into the underlying 
pathways have already been gained, yet the exact molecular mechanisms linking ROS 
formation to atherogenesis are poorly understood. 
The adaptor protein p66Shc was first described as an aging gene in p66Shc
-/-
 mice 
where its deletion was shown to increase life span by 30%. In later studies,  p66Shc
-/-
 mice 
developed less atherosclerotic plaques, reduced hyperglycemia-dependent endothelial 
dysfunction as well as decreased damage in a model of hind limb ischemia [3, 5-8]. 
p46Shc, p52Shc and p66Shc make up the family of ShcA adaptor proteins with molecular 
masses of 46, 52 and 66 kDa respectively. The 3 isoforms display a common Src-homology 2 
domain, a collagen-homology region, and a phosphotyrosine-binding domain  
(SH2-CH1-PTB). However, the splice variant p66Shc contains a unique N-terminal region 
(CH2) which is crucial for its role as a redox enzyme implicated in mitochondrial ROS 
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formation [9]. The splice variant p66Shc has been shown to increase cellular ROS and 
mediate apoptosis [10]. After phosphorylation on Ser36 by oxidative stress induced protein 
kinase C beta (PKCβ), p66Shc translocates to the mitochondria. There, p66Shc affects 
electron transfer from cytochrome c to oxygen, leading to the formation of the radical H202 
[11]. Triggered by ROS, p66Shc also lowers FOX03a activity which results in a decreased 
expression of the scavengers catalase and manganese superoxide dismutase (MnSOD) [12]. 
Mitochondrial apoptosis involves the release of a variety of oxidant complexes from the 
mitochondrial intermembrane space into the cytoplasm. This process is mediated in part by 
permeability transition pore (PTP), a mitochondrial membrane channel protein. It is 
hypothesized that one of the downstream effects of p66Shc is the opening of this pore [11, 
13]. Thus, p66Shc seems to be embedded in a system sensing cellular stresses and translating 
them into an increase of cellular ROS, eventually inducing the apoptotic cascade. 
Overall, p66Shc is a promising therapeutic target for, and marker of ROS-related 
cardiovascular diseases. However, human data confirming this hypothesis are still scarce. It 
has been previously reported that p66Shc mRNA levels are higher in peripheral blood 
mononuclear cells of diabetics compared to healthy individuals [14]. Additionally, a recent 
study indicated an association between p66Shc mRNA expression and coronary 
atherosclerosis in humans [15]. 
In this study, we characterized p66Shc expression levels in peripheral blood 
monocytes of subjects with stable coronary artery disease (CAD) and acute coronary 
syndrome (ACS) compared to healthy individuals without angiographic signs of coronary 
atherosclerosis. Additionally, we evaluated whether p66Shc expression correlates to plasma 
levels of malondialdehyde (MDA), a marker of lipid peroxidation and systemic oxidative 
stress. 
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Materials and Methods 
 
Patient data 
Male subjects aged 54 to 65 years admitted to the cardiac catheterization laboratory at 
the University Hospital Zurich between December 2009 and September 2011 for coronary 
angiography were included in the study. Patients diagnosed with diabetes mellitus, as well as 
individuals suffering from an active neoplastic, infectious of autoimmune disease were not 
included in the study population. For the CAD group, a history of ACS < 6 months prior to 
the study was considered as an exclusion criterion. Ethical approval was granted by the 
institutional ethical committee. All subjects signed an informed consent form. 
 
Data acquisition procedures  
Blood withdrawal took place either during cardiac catheterization from the iliac artery 
or during routine sampling at hospital admission from the antecubital vein. The degree of 
coronary atherosclerosis was determined by quantitative coronary angiography by the 
interventional cardiologist performing the catheterization blinded to the results of the p66Shc 
expression level. Criteria for study group assignment were a) no angiographically identifiable 
local stenosis (>20%) or diffuse wall sclerosis for the control group, b) at least one stenosis ≥ 
75% in either left, circumflex or right coronary artery for the CAD group and c) either a ST-
elevation (typical chest pain and two ST segment elevations ≥ 0.1mV) or a non-ST-elevation 
(typical chest pain with ≥ four-fold elevation of Troponin T) myocardial infarction, both 
being admitted for percutaneous coronary intervention, for the ACS group. 
All patients underwent a general clinical examination and the medical history was 
recorded. Previous medication was not discontinued for the purpose of this study. Blood 
pressure was measured in horizontal position using automatic blood pressure meters. Weight 
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was measured on hospital admission and BMI calculated accordingly. Smoking was defined 
as cigarette consumption of > 10 cigarettes / day. Blood parameters were measured on 
automated routine analyzers. High density lipoprotein cholesterol was measured on Cobas 
Integra (Roche). Plasma concentrations of AST, ALT, total cholesterol, triglycerides, C-
reactive protein (CRP), creatinine, and glucose were measured on Modular Analytics (Roche) 
and Cobas 8000 (Roche).  
 
Isolation of peripheral blood monocytes 
Blood was collected in Ficoll tubes (Vacutainer CPT, BD Diagnostics) and centrifuged 
for 20 minutes at 1’800×g and room temperature. The turbid white layer above the Ficoll 
containing the mononuclear blood cells was transferred to a clean tube and washed twice with 
PBS. Subsequently, monocytes were isolated using magnetic CD14-coated beads and 
magnetic activated cell sorting (MACS). Finally, isolated cells were resuspended in TRIzol 
reagent (Invitrogen) and the total RNA extract was stored at -80°C. 
 
Preparation of cDNA and quantitative real-time PCR 
RNA was further purified from the TRIzol extract with 20% chloroform, centrifuged 
and precipitated from the resulting water phase with isopropanol. Subsequently, the RNA was 
washed with 70% ethanol, the RNA pellet was resuspended in diethylpyrocarbonate (DEPC) 
water and the RNA concentration was measured with a spectrophotometer (NanoDrop, 
Thermo Scientific). Reverse transcription of RNA was performed with the Ready-To-Go 
You-Prime First-Strand Beads (Amersham Biosciences). RNA was heated at 65° Celsius for 
10 minutes. 2 μg of RNA was reverse transcribed with random hexamer primers (pd(N)6; 1 
μg/μl) (TaKaRa) at 37° Celsius for 1 hour. Finally, quantitative real-time PCR was performed 
using the TaqMan Gene Expression Assay (Applied Biosystems
TM
) on a 7500 Fast Real-Time 
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PCR System (Applied Biosystems
TM
). Each reaction contained cDNA, p66shc specific 
TaqMan
®
 MGB probes and primers (specific for the CH2 region) (20x) with a FAM
TM
 
reporter dye (predesigned by Applied Biosystems
TM
), TaqMan
® 
Universal PCR Master Mix 
(2x) (containing AmpliTaq Gold
®
 DNA Polymerase, AmpErase
®
 UNG, dNTPs with dUTP, 
passive reference, and optimized buffer components) and H2O. Samples were run in duplicate 
and the human p66shc gene expression data were normalized against human 18S rRNA 
levels. Quantification was performed using 2
-ΔΔCt
 method. 
 
Measurement of malondialdehyde 
MDA, an end product of lipid peroxidation, is an established marker for oxidative 
stress. Plasma levels of MDA were measured using the thiobarbituric acid-reactive substances 
(TBARS) assay, as described previously [16]. 
 
Statistical analysis 
Continuous variables are expressed as median (interquartile range) and frequencies for 
categorical variables. p66Shc mRNA levels were analyzed by the nonparametric Kruskal-
Wallis-H test, followed by the Mann-Whitney-U test. Clinical data was analyzed by the χ² test 
for categorical and by the Mann-Whitney-U test for continuous data. Spearmans’s correlation 
analysis was used to assess correlation between variables. In figures, data are displayed as 
boxplot (whiskers after tukey and median). The inclusion of 14 patients in each group, for a α-
value of 0.05 (two-tailed; assuming a difference in densitometric unit of 0.1 and a standard 
deviation of 0.08), has the power to detect a significant difference of 91%. The level of 
significance was defined as a two-tailed p value < 0.05. All statistical analyses were 
performed with SPSS Statistics 19.0 for Windows (SPSS, Inc. 2010). 
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Results 
 
Patients characteristics 
In this study, expression of p66Shc mRNA was measured in monocytes isolated from 
blood from 18 ACS patients, 19 CAD patients and 16 age-matched, angiographically 
confirmed healthy controls. Overall median age was 61 years and all patients were of 
caucasian ethnicity. In the CAD group, 4 subjects (21%) had one, 4 (21%) had two and 11 
(58%) had three vessel disease. The ACS group consisted of 7 (39%) STEMI and 11 (61%) 
NSTEMI patients, of which 9 (50%) had an occlusion of the left anterior, 3 (16%) of the 
circumflex and 6 (33%) of the right coronary artery. Myocardial infarction has been 
documented with electrocardiography, angiographic findings and laboratory markers of 
myocardial necrosis, i.e. troponin t and creatine kinase. Clinical data profile differed between 
groups in smoking status, aspirin, clopidogrel and statin usage, blood glucose, total 
cholesterol, and LDL levels (Table 1). 
 
p66Shc expression is increased in patients with acute coronary syndrome  
p66Shc mRNA levels were significantly higher in ACS patients (2.84×10
-5 
  
[2.1×10
-5–5.53×10-5], n = 18) compared to healthy controls (2×10-5   
[1.19×10
-5
-2.78×10
-5
], n = 16; p = 0.0249) or compared to CAD patients (1.73×10
-5 
  
[0.98×10
-5–2.23×10-5], n = 19; p = 0.007) (Figure 1). However, expression levels of p66Shc 
did not differ significantly between CAD patients and healthy controls (p = 0.367) (Figure 1). 
 
p66Shc expression correlates to levels of lipid peroxidation 
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MDA plasma levels measured by TBARS assay were significantly increased in ACS 
patients (1.261 [1.193-1.297], n = 15) compared to healthy controls (1.186 [1.164-1.236], n = 
14; p = 0.029) and to CAD patients (1.135 [1.120-1.161], n = 17; p = 0.0002) (Figure 2). 
MDA levels in CAD patients were lower than in healthy controls (p = 0.006) (Figure 2). The 
MDA plasma concentration correlated significantly with p66Shc mRNA expression levels  
(r = 0.376; p = 0.01) (Figure 3). 
CRP levels were significantly elevated in ACS patients (3.3 [1.4–5.3], n = 18) in 
comparison with healthy controls (1.1 [0.6–1.9], n= 16; p = 0.001) as well as in comparison 
with CAD patients (1.6 [0.7-2.5], n = 17; p = 0.006) (Figure 4). However, no significant 
difference in CRP plasma concentrations was found between CAD patients and healthy 
controls (p = 0.481).  
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Discussion 
 
In this study, we report elevated levels of p66Shc mRNA in peripheral blood 
monocytes of patients who suffered from an acute myocardial infarction but not in those who 
display stable CAD. Plasma levels of MDA, an established marker of lipid peroxidation and 
thus oxidative stress, correlated positively to p66Shc expression. These findings allow the 
speculation that p66Shc may be an interesting novel biomarker associated to adverse 
cardiovascular events or that p66Shc may even play a role in mediating acute vascular 
complications rather than in the preceding chronic phase of coronary atherosclerosis. Surely 
enough, further work made on a prospective basis will be needed to address the above.  
In 2005, Pagnin et al. [14] reported an elevation of p66Shc mRNA in peripheral blood 
monocytes of patients with diabetes type 2 compared to non-diabetic controls indicating that 
p66Shc is responsive to conditions of elevated ROS in humans. We therefore excluded 
diabetic patients to avoid diabetes as a possible confounding factor for p66Shc expression 
levels. Furthermore, the authors described that p66Shc mRNA levels correlated to plasmatic 
levels of 8-isoprostane, a marker of systemic oxidative stress. A recent study by Noda et al. 
[15] explored the association of p66Shc mRNA expression with CAD. The authors compared 
angiographically confirmed controls without CAD to CAD patients but did not include an 
ACS group. In that study, a higher expression of monocytic p66Shc mRNA was measured in 
the CAD group as compared to the healthy control group. However, the oxidative stress 
marker 8-hydroxy-2’-deoxyguanosine (8-OHdG) was not found to be increased in CAD 
patients and did not correlate with p66Shc mRNA levels. These data appear in contradiction 
to our data and those reported by Pagnin et al. where levels of p66Shc were only reported to 
be increased in conditions of increased oxidative stress. Furthermore, in line with the above, 
we report unchanged p66Shc levels in CAD patients. 
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In the study by Noda et al., diabetes was not considered as an exclusion criterion and 
the proportion of patients on diabetes treatment was doubled in the CAD group compared to 
controls. Based on the previous study by Pagnin et al., this might explain why Noda et al. 
reported an elevated p66Shc expression in the CAD group. In the here reported study, diabetic 
patients were excluded, as confirmed by the comparable HbA1c levels observed between the 
three groups. The increased blood glucose levels found in the ACS group in our study are 
likely due to transient hyperglycemia during acute myocardial infarction, as frequently 
reported before [17]. Other differences in the study populations such as ethnicity, mean age, 
inclusion of females and use of medication could account in part for the discrepant results. 
The elevated plasma MDA levels that we observed in the ACS group are in agreement 
with previous studies showing increased levels of systemic oxidative stress measured by 
different markers in the context of myocardial infarction, before as well as after 
revascularization [18-20]. p66Shc has been shown to be involved in ROS regulation in vitro 
[11, 13] and in vivo [7]. Thus, the question arises whether p66Shc plays a role in determining 
the fate of a CAD patient with respect to the development of acute complications such as 
myocardial infarction. In the past, cell death in atherosclerotic plaques has been thought to be 
of necrotic nature [21]. However, it was recently shown that also apoptosis of different cell 
types is largely prevalent at plaque sites and may contribute to plaque cap destabilization and 
consequent plaque rupture [22]. In a histological study, apoptosis of macrophages and foam 
cells was increased at locations of plaque rupture [23]. Furthermore, apoptosis of vascular 
smooth muscle cells has been shown to destabilize atherosclerotic plaques [24]. 
Consequently, the balance between proliferation and death of key cells in the atherosclerotic 
plaque may determine a shift to a more athero- and thrombogenic state [25]. p66Shc is tightly 
linked to apoptosis; it plays an essential role in p53-dependent apoptosis in mice embryo 
fibroblasts and furthermore, its overexpression leads to a higher rate of apoptosis in the same 
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cells [6, 13]. In aortic sections of p66Shc knockout mice fed a high fat diet, the frequency of 
vascular cell apoptosis was lower compared to wildtype [7]. The here reported data 
demonstrate an acute rise in p66Shc and ROS levels in ACS patients but not in CAD ones. 
Thus, it could be hypothesized that p66shc, through its proapoptotic properties, is involved in 
the acute destabilization of a stable CAD patient. 
Markers of oxidative stress such as MDA or 8-isoprostane have been previously 
correlated to the presence of CAD [26]. However, our study did not confirm this finding. This 
may be explained by good control of risk factors in the study population, as demonstrated by 
intensive medical therapy, levels of cholesterol and frequency of smoking (Table 1). 
Furthermore, different studies reported oxidative stress lowering effects of commonly used 
pharmaceuticals for CAD patients such as statins, aspirin and beta-blockers [27, 28]. In the 
CAD group included in this study, aspirin and statin usage was significantly increased 
compared to the other groups. Differences in the intake of beta-blocking agents were not 
significant but notably, relative frequency was still nearly doubled between the control and 
the CAD patients. 
In this study, CRP levels were increased in the ACS group compared to the control 
group and the CAD group. Previous reports demonstrated that CRP is an independent risk 
factor for ACS and in line with this notion CRP has been included in algorithms for risk 
prediction. As described above, the finding that CRP was not elevated in the CAD group 
could be due to good control of risk factors. An association between levels of CRP and 
p66Shc mRNA was not observed in the present study. Thus, our data do not support a direct 
link between p66Shc expression and inflammation but rather only a specific correlation to 
increased ROS levels. 
 In addition, we found a significant correlation between plasma levels of LDL 
cholesterol and p66Shc mRNA expression in monocytes (data not shown). This finding is in 
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line with previously reported data showing a correlation between plasmatic levels of LDL 
cholesterol and p66Shc mRNA in white blood cells of pacemaker patients [29]. 
There is a multitude of contributing factors to the development of atherosclerosis and, 
complete elucidation of all molecular mechanisms is a very complex task. The few clinical 
data currently available on p66Shc’s role in human cardiovascular disease underscore the 
need for further clinical research to address it. Atherosclerosis is currently regarded as an 
inflammatory disease with immune cells such as monocytes and macrophages as established 
key players [30]. For this reason and because of the simple acquisition procedure from blood 
samples, peripheral blood monocytes were selected for this study. Measuring p66Shc in 
endothelial cells or in atherosclerotic plaque tissue would offer interesting additional insights, 
yet sample acquisition from humans poses practical and ethical barriers.  
In summary, our data suggest that p66Shc may be an interesting novel biomarker 
associated to major adverse cardiovascular events; furthermore, p66Shc may play a role in 
mediating the transition between a stable CAD and an acute ACS patient. Further prospective 
studies will be needed to address this hypothesis.  
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Figure captions 
 
Figure 1. p66Shc mRNA expression, relative to expression of 18S rRNA, in peripheral blood 
monocytes from angiographically confirmed CAD-free controls, stable CAD patients and 
patients with ACS. 
 
Figure 2. Plasma concentrations of the oxidative stress marker malondialdehyde (MDA) in 
the three patient groups.  
 
Figure 3. Scatterplot of monocytic p66Shc mRNA expression, relative to ribosomal protein 
S18, and plasma levels of malondialdehyde (MDA) (r = 0.376, p = 0.01). 
 
Figure 4. C-reactive protein (CRP) plasma concentrations in the three patient groups. 
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Table legends 
 
Table 1. Characteristics of study participants. 
 
 
 
  
Point by point response 
 
 
Reviewer #1: 
 
Q1. In the method section, the authors have not indicated which specific primers and probe 
they used for p66shc mRNA quantification. Did they use probes specific for CH2 region of SHC 
gene? This should be included 
A1. For the determination of p66shc gene levels we used a primer/probe mix specific for p66shc, 
predesigned by Applied Biosystems
TM
. The primer/probe anneals within the first 350 bp region of 
p66shc cDNA, indeed the CH2 region as pointed out by the reviewer. This 350 bp are unique and 
specific for p66shc. This information has now been added to the relevant M&M section in the 
manuscript. 
 
Q2. In the method section, the authors wrote that they used ribosomal protein S18 mRNA 
levels to normalize the data in p66shc quantification which has not the same expression of 
p66shc since this latter is really low expressed in leukocytes. Usually, it is better to use 
housekeeping genes with an expression level similar to the one of the gene of interest and this 
is not the case since p66shc in leukocytes is really low expressed. Did the authors try also 
other housekeeping genes? 
A2. First of all we would like to apologize to the reviewer since, following his valuable comment we 
found that we misspelled the type of housekeeping gene we used. Indeed, we used 18S rRNA levels 
(not ribosomal protein S18 mRNA as mentioned in the first version of the manuscript) to normalize our 
p66shc gene expressions. 
One of the most important steps in gaining reliable data for the determination of gene levels using 
quantitative PCR, is the selection of an appropriate endogenous control (housekeeping gene). 
Generally, any gene shown to be expressed at the same level in all study samples can potentially be 
used as an endogenous control. Nevertheless, it is critical to determine if the study design is affecting 
the level of the endogenous gene.  
In our study, we used 18S rRNA levels to normalize our p66shc gene expressions. 18S rRNA is a 
widely used endogenous control and it is known to be uniformly expressed in cells. In our study, only 
small variations of 18S rRNA levels between the samples were observed, also indicating a uniform 
expression of this gene in our experimental setup. Although, no other housekeeping genes were 
tested, we are confident to assume equal results if other housekeeping genes would be used for the 
normalisation. 
 
Q3. MDA is a well known oxidative stress marker but it is also subjected to many interferences 
and other markers such as 8-isoprostanes are preferable. 
A3. We additionally investigated concentrations of 8-isoprostane by analyzing frozen plasma samples 
of our patients, as requested. Unfortunately however, the commercially available competitive 
*Point-by-Point Response
Page 2/8 
immunoassay (Cayman Chemicals, USA) measured no relevant levels of 8-isoprostane in all our 
samples. Indeed, 8-isoprostane concentrations in all groups were up to 10
2
-fold lower than reported in 
previous studies
1-3
 (Figure 1, lower panel). We explain those results by the fact that no antioxidative 
agents such as butylated hydroxytoluene (BHT) or indomethacine (to prevent the ex vivo formation of 
other prostaglandins that might interfere with the assay), were added to our samples before storage, 
which is highly recommended by the producer for carrying out 8-isoprostane measurements posthoc. 
Since additional analysis of indicators of oxidative stress was not planned originally, no such agents  
 
Figure 1. Plasma levels of troponin t and 8-isoprostane by patient group 
preventing degradation of oxidation products were added during preparation of samples for storage. 
However, to reinforce our argumentation for an increased ROS level in ACS patients, the following 
points can be considered. 
The presence of raised levels of 8-isoprostane in ACS patients is an established notion
1,4
. 
Documentation of acute coronary events in the ACS patients enrolled in the present study is very 
thorough with electrocardiography, radiological findings on coronary angiography and quantitative 
results of laboratory markers for the diagnosis of myocardial infarction (troponin t). In line with this, 
troponin t levels were increased in the acs group (Figure 1, upper panel). The reference range for 
troponin t in the laboratory where our analyses have been performed is 0-0.014μg/l and anything 
above is considered pathological. 
Therefore, we are very confident that those patients did indeed suffer an ACS which is inevitably 
associated with increased ROS. Even though it was not possible to provide reliable data on 8-
Page 3/8 
isoprostance from our samples, it can be assumed that those levels were increased at the moment of 
blood withdrawal from subjects in the ACS group. 
Additionally, a positive correlation between p66Shc mRNA expression and total plasma 8-isoprostanes 
was previously reported by Pagnin E et al.
5
 in a study comparing diabetic to non-diabetic patients. This 
finding by another group further supports our hypothesis that p66Shc mRNA and oxidative stress are 
associated and we provide evidence for this with a different marker of oxidative stress, namely MDA. 
Additionally, there is evidence showing a good correlation of MDA levels to 8-isoprostanes in vivo
6
 and 
MDA has been shown to discriminate well and with improved accuracy over 8-isoprostane between 
different states of oxidative stress during cardiac surgery
7
. 
The evaluation of an additional marker of oxidation in this study would have certainly given further 
support to our data but given the issues discussed above, we feel it is not indispensable for reaching 
our conclusion. 
 
Q4. The authors found a lower MDA level in CAD patients compared to controls, which is not 
perfectly in agreement with literature, as they reported. They explained this discrepancy with a 
good control of the patients and the use of statins and aspirin but, in table 1, it is indicated also 
the use of <beta>-blockers for the 53% of the CAD patients versus the 27% and 21% in controls 
and ACS patients respectively. It is well demonstrated that many anti-hypertensive drugs have 
antioxidant effects and also <beta>-blockers show this peculiarity. This could be in part an 
explanation for the "abnormal" MDA values in these patients and should be indicated in the 
discussion session. 
We thank the reviewer for this valuable comment. The low MDA concentrations in stable CAD patients 
cannot be explained with absolute certainty, as conclusions about causality cannot be drawn with an 
observational study design like the present one. In general, questions about causal relations in 
oxidative stress pathways are extremely challenging in humans. As reviewer #1 pointed out, oxidative 
stress lowering effects of different pharmaceuticals prescribed for CAD patients are well established; 
the explanatory hypothesis of decreased MDA levels due to a significantly increased intake of multiple 
oxidative stress lowering medications in the CAD group seems reasonable. 
The difference in frequency of beta-blockers intake between the groups studied was below the level of 
significance; e.g. the chi-squared test comparing the numbers of beta-blocker users between stable 
CAD patients and ACS patients resulted in a p value of 0.10, even though the relative frequency of 
beta-blocker intake was more than doubled in the CAD group as compared to ACS. Following the 
suggestion of the reviewer, we have now included beta-blockers in the appropriate paragraph of the 
discussion where we describe the possible influence of pharmaceutical on levels of oxidative stress in 
the CAD group (changes in the manuscript are shown in red). 
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Reviewer #2: 
 
The authors should be commended for this manuscript and this reviewer has only positive 
comments about this manuscript. 
 
 
 
 
Page 5/8 
Reviewer #3: 
 
Q1. Sample size is small and should be increased to confirm data and correlation. 
A1. A sample size calculation based the decision on the number of patients to be included and the 
final results showed statistical significance. Nonetheless, we agree with the comment of the reviewer 
and we recruited additional patients throughout the time we had available for submitting the revisions 
of the present study. 
The sample size in the 3 experimental groups included in this study was raised from 15, 17 and 14 in 
healthy, CAD and ACS respectively to 16, 19 and 18. 
The authors would like to add that compared to similar studies where the levels of p66Shc were 
assessed in diabetic (Pagnin, et al.
5
) or CAD patients (Noda, et al.
8
), the number of patients/group 
included in this study now is higher or equal, respectively. 
 
Q2. As MDA provided somehow inconsistent results (lower levels in CAD vs controls remain 
essentially unexplained), at least another plasma marker of oxidative stress should be 
determined in parallel (i.e. TBARS, isoprostanes, SOD, catalase, ...). This should be easily done 
using frozen samples.. 
A2. We thank the reviewer for this valuable comment. The low MDA concentrations in stable CAD 
patients cannot be explained with absolute certainty, as conclusions about causality cannot be drawn 
with an observational study design like the present one. In general, questions about causal relations in 
oxidative stress pathways are extremely challenging in humans.  
Oxidative stress lowering effects of different drugs prescribed for CAD patients are well established; 
thus, the argument of decreased MDA levels due to a significantly increased intake of multiple 
oxidative stress lowering medications (e.g statins, beta blockers and aspirin) in the CAD group seems 
reasonable. 
Nevertheless, as requested by the reviewer we performed 8-isoprostane measurements in the 3 
experimental groups included in this study so as to provide further evidence for an augmented ROS 
production in the ACS group. 
Unfortunately however, the commercially available competitive immunoassay (Cayman Chemicals, 
USA) measured no relevant levels of 8-isoprostane in all our samples (Figure 1, lower panel). Indeed, 
8-isoprostane concentrations in all groups were up to 10
2
-fold lower than reported in previous studies
1-
3
. We explain those results by the fact that no antioxidative agents such as butylated hydroxytoluene 
(BHT) or indomethacine (to prevent the ex vivo formation of other prostaglandins that might interfere 
with the assay), were added to our samples before storage, which is highly recommended by the 
producer for carrying out 8-isoprostane measurements posthoc. Since additional analysis of indicators 
of oxidative stress was not planned originally, no such agents preventing degradation of oxidation 
products were added during preparation of samples for storage. 
However, to reinforce our argumentation for an increased ROS level in ACS patients, the following 
points can be considered.  
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The presence of raised levels of 8-isoprostane in ACS patients is an established notion
1,4
. 
Documentation of acute coronary events in the ACS patients enrolled in the present study is very 
thorough with electrocardiography, radiological findings on coronary angiography and quantitative 
results of laboratory markers for the diagnosis of myocardial infarction (troponin t). In line with this, 
troponin t levels were increased in the acs group (Figure 1, upper panel). The reference range for 
troponin t in the laboratory where our analyses have been performed is 0-0.014μg/l and anything 
above is considered pathological. 
 
Figure 1. Plasma levels of troponin t and 8-isoprostane by patient group 
 Therefore, we are very confident that those patients did indeed suffer an ACS which is inevitably 
associated with increased ROS. Even though it was not possible to provide reliable data on 8-
isoprostance from our samples, it can be assumed that those levels were increased at the moment of 
blood withdrawal from subjects in the ACS group. 
Additionally, a positive correlation between p66Shc mRNA expression and total plasma 8-isoprostanes 
was previously reported by Pagnin E et al.
5
 in a study comparing diabetic to non-diabetic patients. This 
finding by another group further supports our hypothesis that p66Shc mRNA and oxidative stress are 
associated and we provide evidence for this with a different marker of oxidative stress, namely MDA. 
Additionally, there is evidence showing a good correlation of MDA levels to 8-isoprostanes in vivo
6
 and 
MDA has been shown to discriminate well and with improved accuracy over 8-isoprostane between 
different states of oxidative stress during cardiac surgery
7
. 
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The evaluation of an additional marker of oxidation in this study would have certainly given further 
support to our data but given the issues discussed above, we feel it is not indispensable for reaching 
our conclusion 
 
Q3. Was there any correlation between p66Shc gene expression and CRP? If not, it may be 
worth stressing that oxidative stress and not inflammation is related to p66Shc biology. 
A3. We fully agree with the statement of the reviewer in fact, no correlation between p66 and CRP was 
present in our study. In line with this, we have rephrased the relevant parts of the discussion where 
this aspect is argued (changes in the discussion are shown in red). 
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Dear Dr. Fadini 
  
Thank you for taking our manuscript into consideration. We reassessed all critical points raised by the 
reviewers and are pleased to resubmit our paper as well as the answers to the respective questions. 
 
Although we addressed the vast majority of the points raised by the reviewers, we were faced with 
some technical problems concerning the requested 8-isoprostane measurement. Indeed, our samples 
had not been stored with antioxidants rendering them unsuitable for new isoprostane measurements 
(which we anyway tried to perform as shown in the point by point response). Nevertheless, we offer 
additional evidence to support elevated ROS levels in the ACS patients we enrolled in this study and 
we are convinced that such information will address the reviewer’s concerns on this issue. 
 
Changes in the manuscript are highlighted in red as required in the instructions to authors and 
responses to specific questions are given below. 
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Group
Control (n=16) CAD (n=19) ACS (n=18)
Gender (m/f) 16/0 19/0  18/0
60 (55-63) 61 (57-64) 59.5 (57-61)
134 (128-136) 135 (125-143) 132.5 (119-148)
80 (75-86) 78 (70-83) 83.5 (72-90)
27.6 (24.8-29.8) 27.8 (24.5-31.1) 27.2 (25.1-30.4)
5.6 (5.4-6.1) * 5.9 (5.4-6.0) * 6.2 (5.9-6.8)
0.056 (0.055-0.059) 0.058 (0.056-0.060) 0.06 (0.057-0.061)
4.45 (3.5-5.05) 4.2 (3.9-5.0) * 5.0 (4.5-6.0)
2.45 (1.98-3.07) * 2.3 (2.0-3.1) * 3.2 (2.8-4.1)
1.19 (1.08-1.34) 1.22 (0.94-1.47) 1.13 (0.9-1.37)
0.85 (0.66-1.44) 1.12 (0.75-1.86) 1.14 (0.84-1.79)
28 (18-36) 31 (20-44) 38 (30-49)
1.1 (0.6-1.9) * 1.6 (0.7-2.5) * 3.3 (1.4-5.3)
Creatinine (μmol/l) 83 (78-94) 95 (82-98) 82.5 (78-108)
14.4 (14.1-15.1) 14.4 (13.7-15.1) 14.4 (13.7-15.2)
Malondialdehyde (nmol/l) 1.186 (1.164-1.236) ● * 1.135 (1.12-1.161) * 1.261 (1.193-1.297)
p66shc (x10e-5,arbitrary units) 2.0 (1.19-2.78) * 1.73 (0.98-2.23) * 2.84 (2.1-5.53)
Hypertension 8 (50%) 13 (68%) 12 (67%)
Current smoking 4 (25%) 3 (16%) 10 (56%) ●
Dyslipidemia 5 (31%) 12 (63%) 11 (61%)
Obesity (BMI ≥ 30) 4 (25%) 6 (32%) 6 (33%)
Aspirin 8 (50%) ● 17 (89%) 10 (56%) ●
Clopidogrel 0 (0%) ● 7 (37%) 2 (11%)
ACE-inhibitor 9 (56%) 10 (53%) 9 (50%)
Betablocker 4 (25%) 9 (47%) 4 (22%)
Diuretics 3 (19%) 4 (21%) 2 (11%)
Statin 6 (38%) ● 16 (84%) 7 (39%) ●
Calcium antagonist 1 (6%) 3 (16%) 3 (17%)
Data are expressed as median (interquartile range) or count (percentage)
● p < 0.05 compared to CAD group
* p  < 0.05 compared to ACS group
Age (y)
BMI (kg/m²)
Glucose (mmol/l)
HbA1c
BP syst. (mmHg)
Total cholesterol (mmol/l)
ALT (U/I)
CRP (mg/l)
Hb (gr/dl)
LDL cholesterol (mmol/l)
Abbreviations: ACE-inhibitor, Angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; BMI, body mass index; BP 
diast., diastolic blood pressure; BP syst., systolic blood pressure; CRP, C-reactive protein; f, female; HbA1c, glycosylated hemoglobin; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; m, male; y, years.
BP diast. (mmHg)
HDL cholesterol (mmol/l)
Triglycerides (mmol/l)
Table(s)
